SAN JUAN, Puerto Rico, Nov. 3, 2014 (GLOBE NEWSWIRE) -- GB Sciences (OTCQB:GBLX), a company that merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize safe and consistent medicinal cannabis, will host its first annual medical cannabis conference on November 14th.
This premiere event, titled "Cannabinoid Science and Medicine: From Plant to Medicine," will start at 9:30 a.m on November 14, 2014, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. Co-sponsored by parent GB Sciences and GB Sciences Puerto Rico (GBPR), the event will be cohosted by Dr. José A. Franceschini, Chief Medical Officer of GBPR, and Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences.
"Education is the key to providing access for the hundreds of thousands of people around the world who suffer from Alzheimer's, Parkinson's, epilepsy, and so many other diseases that would benefit from pharmaceutical-grade cannabis products," says Dr. Small-Howard. "This educational event will benefit participants by arming them with scientific and medical facts that are not widely available."
The conference is intended to communicate the latest scientific developments on the utility and efficacy of cannabinoid therapies and to dispel the myths that persist about cannabis, myths that have delayed the acceptance of cannabis as legitimate medicine. The conference will also emphasize economic benefits that are anticipated for Puerto Rico as a result of the clinical trial programs planned by GB Sciences and the extensive operations planned by GBPR.
Speakers include some very knowledgeable people in the medical cannabis industry:
- Andrea L. Small-Howard, PhD, MBA: GB Sciences' Chief Science Officer has developed a novel drug discovery engine to find and then validate proprietary cannabinoid therapies through clinical trials planned in Puerto Rico.
- Craig Ellins: The CEO of GB Sciences has spent years studying cannabis cultivation and supply-chain methods in order to create an unparalleled system for growing, processing, and dispensing medical cannabis that is consistent and safe.
- José A. Franceschini Carlo, MD, FAPA: As the Chairman of the Department of Psychiatry at the Universidad Central Del Caribe, Dr. Franceschini is one of the best informed and most outspoken supporters of the use of cannabinoid therapies in Puerto Rico.
- Helen Turner, PhD: Dean of Natural Sciences and Mathematics at Chaminade University and well respected immunologist, Dr. Helen Turner is working with GB Sciences to develop preclinical trials for proprietary cannabinoid therapies and a CME-accredited cannabis educational program for physicians and GB Sciences' staff.
"Please join us for this eye-opening symposium on the benefits of cannabinoid treatment," invites Dr. Franceschini. "But reserve your spot soon—we expect a full capacity audience in this invitation only event."
About GrowBLOX Sciences, Inc.
GB Sciences merges state-of-the-art technologies in plant biology, cultivation technology, and post-production processes in order to optimize our safe and consistent medicinal cannabis. The company is pioneering technology, industry-leading processes, and a big-data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
To learn more about GB Sciences, Inc., go to www.gbsciences.com.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Media and Investor Relations Contact: Stephen Hart Hayden IR email@example.com 917-658-7878Source:GrowBlox Sciences Inc